We did it!! I am really honoured to lead this important FIH study! A novel transurethral robotic system that can make ERBT much easier, and hopefully we can generalize the technique to every urologist globally. A better surgery will lead to better outcomes!! 🌎 #UroSoMe

🎥Check out this interview with Sam S. Chang MD, MBA at UroToday.com 🗣️We discuss about TAR-200 in BCG unresponsive papillary-only patients 🥨Recent data presented at #AUA25 Amer. Urol. Assn. GUARD Consortium UroSoMe CANVES Alianza por el Cáncer de Vejiga en España GUO-AEU #bladdercancer t.ly/XBZJF

Una visión científica, integradora y útil. Me presento como candidato a Director de Actividades Científicas de la Asociación Española de Urología AEU con propuestas claras: •Alianzas con instituciones públicas y privadas •Apoyo metodológico y estadístico •Red AEU de

🔍 How Can AI Improve Urology Research Readability? 🤖 AI Tools models can significantly improve text clarity 📚 Enhanced readability increase research accessibility tnyp.me/kV3BWguM

🔥⚡️🚀New editorial in Transl Androl Urol! We discuss how PSMA-PET/CT is transforming salvage RT in prostate cancer. Thanks to Elísabet Gonzalez del Portillo, Fernando Lopez Campos , Paul Sargos . Read: tau.amegroups.org/article/view/1… #ProstateCancer #PSMAPET

FDA ODAC: 5–4 votes against UGN-102 in IR #NMIBC, and raises a critical point that even though data ‘looked good’, there are questions which can only be clarified via a well-designed RCT cancernetwork.com/view/fda-odac-… via CancerNetwork® Roger Li Shilpa Gupta IBCG

Ashish M. Kamat, MD, MBBS CancerNetwork® Roger Li Shilpa Gupta IBCG Certainly a RCT needed in this space (easy to recruit pts, ✅ options for control arm like gemcitabine or regular MMC) Can't understand how the CR has gone from 65% (in their two prior trials, ATLAS and OPTIMA-II) to 80% in ENVISION 🧐 pubmed.ncbi.nlm.nih.gov/38721284/ Felipe Villacampa

🤩Privileged to be co-author in this paper on the CREST trial published at Nature Medicine with Tom Powles Matt Galsky Joan Palou Redorta Evanguelos Xylinas Alberto Briganti among others 🙌🏼Thrilled to be part of an eventual paradigm shift in #NMIBC after 50 years 👣This is only the

Adjuvant Nivolumab in MIUC – Real-World Data with a Focus on Disparities led by Alex Chehrazi-Raffle, MD A quick tweetorial 🧵 ⁉️ Can real-world outcomes of adjuvant nivolumab match those from clinical trials? And how does it perform in underrepresented groups? ➡️We evaluated 253 patients

📸 Esta foto demuestra lo que es nuestro congreso nacional #AEU25 🤩 Sonrisas, complicidad, sabiduría y, sobre todo, amigos 🙌🏼 Qué afortunado me siento y qué arropado con ellos! MJosé Juan Óscar Rodríguez Faba Mario AlvarezMaestro 💪🏽 Por muchas más!

Félix Guerrero-Ramos MJosé Juan Óscar Rodríguez Faba Mario AlvarezMaestro Forjando el futuro de la oncología vesical. Muchas gracias por vuestras continuas aportaciones #AEU25 AEU Óscar Rodríguez Faba Mario AlvarezMaestro

🧾 Cheat Sheet on Follow-up for NMIBC 🔹 Risk-based surveillance 🔹 Lifelong follow-up for high-risk patients 🔹 Role of cytology & markers 🔍 No substitute for cystoscopy Download Cheat Sheet: uroweb.org/guidelines/non… #BladderCancer #NMIBC #EAUguidelines

Un placer volver a casa para ayudar en un nuevo implante de esfinter femenino robótico. Una solución efectiva y duradera tratar el déficit esfinteriano. Gracias a Jose Daniel Subiela y a Javier Burgos Revilla por su amable invitacion. Miguel S. Encinas Hosp.Rey Juan Carlos ROC Clinic

Very happy to have contributed to the book primer on Urology with the chapter Carcinoma in Situ of the bladder, together with my colleagues Félix Guerrero-Ramos Jose Daniel Subiela Joan Palou Redorta Alberto Breda ⬇️URL to download the book